AU2158292A - Cea-binding proteins and methods for their isolation and use - Google Patents

Cea-binding proteins and methods for their isolation and use

Info

Publication number
AU2158292A
AU2158292A AU21582/92A AU2158292A AU2158292A AU 2158292 A AU2158292 A AU 2158292A AU 21582/92 A AU21582/92 A AU 21582/92A AU 2158292 A AU2158292 A AU 2158292A AU 2158292 A AU2158292 A AU 2158292A
Authority
AU
Australia
Prior art keywords
cea
isolation
methods
binding proteins
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU21582/92A
Inventor
Joseph V Briggman
Sibusisiwe M Maswoswe
Peter Thomas
Carol A. Toth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
New England Deaconess Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/708,885 external-priority patent/US5245017A/en
Priority claimed from US07/714,386 external-priority patent/US5278290A/en
Priority claimed from US07/708,888 external-priority patent/US5281697A/en
Application filed by New England Deaconess Hospital filed Critical New England Deaconess Hospital
Publication of AU2158292A publication Critical patent/AU2158292A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
AU21582/92A 1991-05-31 1992-05-22 Cea-binding proteins and methods for their isolation and use Abandoned AU2158292A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US07/708,885 US5245017A (en) 1991-05-31 1991-05-31 Method for isolating CEA-binding protein
US714386 1991-05-31
US708888 1991-05-31
US07/714,386 US5278290A (en) 1991-05-31 1991-05-31 Binding protein for CEA and uses thereof
US07/708,888 US5281697A (en) 1991-05-31 1991-05-31 CEA-binding protein and uses thereof
US708885 1991-05-31

Publications (1)

Publication Number Publication Date
AU2158292A true AU2158292A (en) 1993-01-08

Family

ID=27418849

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21582/92A Abandoned AU2158292A (en) 1991-05-31 1992-05-22 Cea-binding proteins and methods for their isolation and use

Country Status (3)

Country Link
EP (1) EP0587777A4 (en)
AU (1) AU2158292A (en)
WO (1) WO1992021364A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774209B1 (en) 2000-04-03 2004-08-10 Dyax Corp. Binding peptides for carcinoembryonic antigen (CEA)
MXPA05005031A (en) 2002-11-12 2005-11-17 Becton Dickinson Co Diagnosis of sepsis or sirs using biomarker profiles.
KR20080006617A (en) 2005-04-15 2008-01-16 백톤 디킨슨 앤드 컴퍼니 Diagnosis of sepsis
US8247370B2 (en) 2006-12-04 2012-08-21 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
US8497243B2 (en) 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
ES2554167T3 (en) * 2007-07-06 2015-12-16 Promedior Inc. Methods and compositions useful in the treatment of mucositis
US8669113B2 (en) 2008-04-03 2014-03-11 Becton, Dickinson And Company Advanced detection of sepsis
JP5797565B2 (en) 2009-03-11 2015-10-21 プロメディオール， インコーポレイテッド Treatment and diagnosis method for hypersensitive disorder
CA2755047C (en) 2009-03-11 2018-12-04 Promedior, Inc. Treatment methods for autoimmune disorders
UA110323C2 (en) 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
ES2552793T3 (en) 2009-06-17 2015-12-02 Promedior Inc. SAP variants and their use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1174800B (en) * 1983-11-21 1987-07-01 Alberto Bartorelli METHOD FOR THE DETERMINATION OF HUMAN IMMUNOGLOBULINS SPECIFIC FOR HUMAN CARCINOMA ANTIGENS AND ITS USE IN THE SERIOUS DIAGNOSIS OF PRIMITIVE TUMOR FORMS
GB8516081D0 (en) * 1985-06-25 1985-07-31 Ciba Geigy Ag Assay & purification of amyloid components
US4914021A (en) * 1988-03-04 1990-04-03 New England Deaconess Hospital Corporation Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses
US4892933A (en) * 1988-04-20 1990-01-09 New England Deaconess Hospital Corporation Monoclonal antibody for colorectal carcinoma

Also Published As

Publication number Publication date
EP0587777A1 (en) 1994-03-23
EP0587777A4 (en) 1995-05-10
WO1992021364A1 (en) 1992-12-10

Similar Documents

Publication Publication Date Title
AP9200376A0 (en) Novel antibodies and methods for their use
AU652928B2 (en) Lipid-selective antioxidants and their preparation and use
AU3379193A (en) Antigen binding proteins and methods for their production
AU3134893A (en) Micro-libraries and methods for making and manipulating them
AU2170592A (en) Protein compositions having reduced-hygroscopic properties and methods for preparing same
AU2514592A (en) Methods and compositions for modulating g protein action
AU4930993A (en) Coupled replication-translation methods and kits for protein synthesis
AU3274889A (en) Picnic trailer apparatus
AU3467493A (en) Histamine derivatives and methods for their use
AU3937289A (en) Hybrid protein c constructs and methods for their preparation
AU7400091A (en) Inhibitors of the advanced glycosylation of proteins and methods of use therefor
AU2158292A (en) Cea-binding proteins and methods for their isolation and use
AU652660B2 (en) Method for purifying factor VIII and preparations obtained
AU1480992A (en) Method and kit for measuring anti-ebna antibodies
AU646173B2 (en) 3-deoxy-mannosamine derivatives and process for their preparation
AU8427091A (en) Gamma-carboxylase and methods of use
AU3890689A (en) Human protein c mutants and method for preparing the same
AU3011692A (en) Horseshoes and method for their preparation
AU4819897A (en) Films having improved characteristics and methods for their preparation and use
AU1070495A (en) Geopolymeric cement and methods for preparing same
AU647559B2 (en) Pyrimidinyl- and triazinyl-salicylamides and their use and preparation
AU7294491A (en) Labdanes and process for their preparation
AU3404293A (en) Novel substituted stannosilicates and preparation thereof
AU5050490A (en) Human monocyte-macrophage-csf preparations
AU6269190A (en) Antibodies and proteins